| Literature DB >> 11554204 |
K L Billups1, L Berman, J Berman, M E Metz, M E Glennon, I Goldstein.
Abstract
Although Female Sexual Dysfunction (FSD) affects 40% of American women, there is no FDA-approved pharmaceutical therapy. The EROS-CTD (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment is the first FDA cleared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitoral engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study was to assess the effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal volunteers and women with FSD.Entities:
Mesh：
Year: 2001 PMID： 11554204 DOI： 10.1080/713846826
Source DB: PubMed Journal: J Sex Marital Ther ISSN： 0092-623X